Potentiation of azole antifungals by 2-adamantanamine

Michael D. LaFleur, Lingmei Sun, Ida Lister, John Keating, Andre Nantel, Lisa Long, Mahmoud Ghannoum, E. Jeffrey North, Richard E. Lee, Ken Coleman, Thomas Dahl, Kim Lewis

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Azoles are among the most successful classes of antifungals. They act by inhibiting 14 lanosterol demethylase in the ergosterol biosynthesis pathway. Oropharyngeal candidiasis (OPC) occurs in about 90% of HIV-infected individuals, and 4 to 5%are refractory to current therapies, including azoles, due to the formation of resistant biofilms produced in the course of OPC. We reasoned that compounds affecting a different target may potentiate azoles to produce increased killing and an antibiofilm therapeutic. 2-Adamantanamine (AC17) was identified in a screen for compounds potentiating the action of miconazole against biofilms of Candida albicans. AC17, a close structural analog to the antiviral amantadine, did not affect the viability of C. albicans but caused the normally fungistatic azoles to become fungicidal. Transcriptome analysis of cells treated with AC17 revealed that the ergosterol and filamentation pathways were affected. Indeed, cells exposed to AC17 had decreased ergosterol contents and were unable to invade agar. In vivo, the combination of AC17 and fluconazole produced a significant reduction in fungal tissue burden in a guinea pig model of cutaneous candidiasis, while each treatment alone did not have a significant effect. The combination of fluconazole and AC17 also showed improved efficacy (P value of 0.018) compared to fluconazole alone when fungal lesions were evaluated. AC17 is a promising lead in the search for more effective antifungal therapeutics.

Original languageEnglish
Pages (from-to)3585-3592
Number of pages8
JournalAntimicrobial Agents and Chemotherapy
Volume57
Issue number8
DOIs
StatePublished - Aug 2013
Externally publishedYes

Fingerprint

Azoles
Ergosterol
Fluconazole
Candidiasis
Biofilms
Candida albicans
Cutaneous Candidiasis
Lanosterol
Miconazole
Amantadine
Gene Expression Profiling
Agar
Antiviral Agents
Guinea Pigs
Therapeutics
HIV

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Pharmacology
  • Infectious Diseases

Cite this

LaFleur, M. D., Sun, L., Lister, I., Keating, J., Nantel, A., Long, L., ... Lewis, K. (2013). Potentiation of azole antifungals by 2-adamantanamine. Antimicrobial Agents and Chemotherapy, 57(8), 3585-3592. https://doi.org/10.1128/AAC.00294-13

Potentiation of azole antifungals by 2-adamantanamine. / LaFleur, Michael D.; Sun, Lingmei; Lister, Ida; Keating, John; Nantel, Andre; Long, Lisa; Ghannoum, Mahmoud; North, E. Jeffrey; Lee, Richard E.; Coleman, Ken; Dahl, Thomas; Lewis, Kim.

In: Antimicrobial Agents and Chemotherapy, Vol. 57, No. 8, 08.2013, p. 3585-3592.

Research output: Contribution to journalArticle

LaFleur, MD, Sun, L, Lister, I, Keating, J, Nantel, A, Long, L, Ghannoum, M, North, EJ, Lee, RE, Coleman, K, Dahl, T & Lewis, K 2013, 'Potentiation of azole antifungals by 2-adamantanamine', Antimicrobial Agents and Chemotherapy, vol. 57, no. 8, pp. 3585-3592. https://doi.org/10.1128/AAC.00294-13
LaFleur MD, Sun L, Lister I, Keating J, Nantel A, Long L et al. Potentiation of azole antifungals by 2-adamantanamine. Antimicrobial Agents and Chemotherapy. 2013 Aug;57(8):3585-3592. https://doi.org/10.1128/AAC.00294-13
LaFleur, Michael D. ; Sun, Lingmei ; Lister, Ida ; Keating, John ; Nantel, Andre ; Long, Lisa ; Ghannoum, Mahmoud ; North, E. Jeffrey ; Lee, Richard E. ; Coleman, Ken ; Dahl, Thomas ; Lewis, Kim. / Potentiation of azole antifungals by 2-adamantanamine. In: Antimicrobial Agents and Chemotherapy. 2013 ; Vol. 57, No. 8. pp. 3585-3592.
@article{68f6b376609c4346a1dbf4f2b36ded6e,
title = "Potentiation of azole antifungals by 2-adamantanamine",
abstract = "Azoles are among the most successful classes of antifungals. They act by inhibiting 14 lanosterol demethylase in the ergosterol biosynthesis pathway. Oropharyngeal candidiasis (OPC) occurs in about 90{\%} of HIV-infected individuals, and 4 to 5{\%}are refractory to current therapies, including azoles, due to the formation of resistant biofilms produced in the course of OPC. We reasoned that compounds affecting a different target may potentiate azoles to produce increased killing and an antibiofilm therapeutic. 2-Adamantanamine (AC17) was identified in a screen for compounds potentiating the action of miconazole against biofilms of Candida albicans. AC17, a close structural analog to the antiviral amantadine, did not affect the viability of C. albicans but caused the normally fungistatic azoles to become fungicidal. Transcriptome analysis of cells treated with AC17 revealed that the ergosterol and filamentation pathways were affected. Indeed, cells exposed to AC17 had decreased ergosterol contents and were unable to invade agar. In vivo, the combination of AC17 and fluconazole produced a significant reduction in fungal tissue burden in a guinea pig model of cutaneous candidiasis, while each treatment alone did not have a significant effect. The combination of fluconazole and AC17 also showed improved efficacy (P value of 0.018) compared to fluconazole alone when fungal lesions were evaluated. AC17 is a promising lead in the search for more effective antifungal therapeutics.",
author = "LaFleur, {Michael D.} and Lingmei Sun and Ida Lister and John Keating and Andre Nantel and Lisa Long and Mahmoud Ghannoum and North, {E. Jeffrey} and Lee, {Richard E.} and Ken Coleman and Thomas Dahl and Kim Lewis",
year = "2013",
month = "8",
doi = "10.1128/AAC.00294-13",
language = "English",
volume = "57",
pages = "3585--3592",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "8",

}

TY - JOUR

T1 - Potentiation of azole antifungals by 2-adamantanamine

AU - LaFleur, Michael D.

AU - Sun, Lingmei

AU - Lister, Ida

AU - Keating, John

AU - Nantel, Andre

AU - Long, Lisa

AU - Ghannoum, Mahmoud

AU - North, E. Jeffrey

AU - Lee, Richard E.

AU - Coleman, Ken

AU - Dahl, Thomas

AU - Lewis, Kim

PY - 2013/8

Y1 - 2013/8

N2 - Azoles are among the most successful classes of antifungals. They act by inhibiting 14 lanosterol demethylase in the ergosterol biosynthesis pathway. Oropharyngeal candidiasis (OPC) occurs in about 90% of HIV-infected individuals, and 4 to 5%are refractory to current therapies, including azoles, due to the formation of resistant biofilms produced in the course of OPC. We reasoned that compounds affecting a different target may potentiate azoles to produce increased killing and an antibiofilm therapeutic. 2-Adamantanamine (AC17) was identified in a screen for compounds potentiating the action of miconazole against biofilms of Candida albicans. AC17, a close structural analog to the antiviral amantadine, did not affect the viability of C. albicans but caused the normally fungistatic azoles to become fungicidal. Transcriptome analysis of cells treated with AC17 revealed that the ergosterol and filamentation pathways were affected. Indeed, cells exposed to AC17 had decreased ergosterol contents and were unable to invade agar. In vivo, the combination of AC17 and fluconazole produced a significant reduction in fungal tissue burden in a guinea pig model of cutaneous candidiasis, while each treatment alone did not have a significant effect. The combination of fluconazole and AC17 also showed improved efficacy (P value of 0.018) compared to fluconazole alone when fungal lesions were evaluated. AC17 is a promising lead in the search for more effective antifungal therapeutics.

AB - Azoles are among the most successful classes of antifungals. They act by inhibiting 14 lanosterol demethylase in the ergosterol biosynthesis pathway. Oropharyngeal candidiasis (OPC) occurs in about 90% of HIV-infected individuals, and 4 to 5%are refractory to current therapies, including azoles, due to the formation of resistant biofilms produced in the course of OPC. We reasoned that compounds affecting a different target may potentiate azoles to produce increased killing and an antibiofilm therapeutic. 2-Adamantanamine (AC17) was identified in a screen for compounds potentiating the action of miconazole against biofilms of Candida albicans. AC17, a close structural analog to the antiviral amantadine, did not affect the viability of C. albicans but caused the normally fungistatic azoles to become fungicidal. Transcriptome analysis of cells treated with AC17 revealed that the ergosterol and filamentation pathways were affected. Indeed, cells exposed to AC17 had decreased ergosterol contents and were unable to invade agar. In vivo, the combination of AC17 and fluconazole produced a significant reduction in fungal tissue burden in a guinea pig model of cutaneous candidiasis, while each treatment alone did not have a significant effect. The combination of fluconazole and AC17 also showed improved efficacy (P value of 0.018) compared to fluconazole alone when fungal lesions were evaluated. AC17 is a promising lead in the search for more effective antifungal therapeutics.

UR - http://www.scopus.com/inward/record.url?scp=84880270967&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880270967&partnerID=8YFLogxK

U2 - 10.1128/AAC.00294-13

DO - 10.1128/AAC.00294-13

M3 - Article

VL - 57

SP - 3585

EP - 3592

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 8

ER -